RxDoctor Payments Data

Joseph Hsu, MD

Ophthalmology · Downey, CANPI 1760584270

Payments from drug & device makers

$2,724in general payments, 2019–2025

Across 69 payments — averaging $39.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Glaukos Corporation$304
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$160
  • Ivantis, Inc$154
  • Aerie Pharmaceuticals, Inc.$151
  • Nova Eye, Inc.$134
  • plus $217 from 6 others

What the payments were for

  • Food & beverage$2,724100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,724 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$184,766
Medicare patients
218
Services billed
2,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine59$48,199
Cyclosporine88$34,973
VyzultaLatanoprostene Bunod45$17,039
RhopressaNetarsudil Mesylate41$15,351
LumiganBimatoprost38$12,702
Prednisolone Acetate169$9,626
XiidraLifitegrast13$9,039
Latanoprost1,025$7,167
CombiganBrimonidine Tartrate/Timolol21$6,663
Brimonidine Tartrate278$4,982
SimbrinzaBrinzolamide/Brimonidine Tart25$4,853
RocklatanNetarsudil Mesylat/Latanoprost15$4,715
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat181$4,230
Timolol Maleate157$4,077
Travoprost37$4,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$1,604$67,565118 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$65$26,07858 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$151$20,06656 claims
AlconSimbrinza$14$4,85325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →